Home / Transcripts / Ipca Laboratories Limited (IPCALAB) · November 5, 2026

Ipca Laboratories Limited (IPCALAB) Earnings Call Transcript

November 5, 2026

National Stock Exchange of India IN Health Care Pharmaceuticals earnings 23 min

Earnings Call Speaker Segments

Operator operator
#1

Ladies and gentlemen, hello, and thank you for joining the Ipca Labs Q2 FY '27 earnings conference call, brought to you by DAM Capital Advisors Limited. <<operator_script>> Kindly be aware that this call is being recorded. At this point, I'll turn the call over to Mr. Nitin Agarwal of DAM Capital Advisors. Thank you, and please go ahead, sir.

Nitin Agarwal analyst
#2

Thank you, and good afternoon to all of you. It's a real pleasure to welcome everyone to the Ipca Labs Q2 F '27 Earnings Call, which DAM Capital Advisors Limited is hosting. Joining us on today's call from Ipca Labs management are Mr. A.K. Jain, Managing Director, and Mr. Harish Kamat, Corporate Counsel and Company Secretary. I'll now pass the call to Mr. Jain for his opening remarks, after which we'll open the floor to questions. Over to you, sir.

Ajit Kumar Jain executive
#3

Thank you, Nitin, and thanks to DAM Capital for putting this call together. The remarks and responses on today's hearing call could contain forward-looking statements that rest on how we currently see the business. These need to be considered alongside the risks that pharmaceutical operations carry. What we actually deliver financially in the future might not match what is projected in Brazil. You should form your own view using the information shared on this call. In Q2 FY '27, our domestic formulation business grew by roughly 14%, reaching about INR 1,157 crores, compared with INR 1,019 crores in Q2 FY '26. As of September 2026, Ipca's ranking stayed at 16, while our market share rose to approximately 2.11% from 2.09% in September '26. Ipca has 6 brands among the industry's top 300 brands. Of those 16 brands, all SP is the company's leading brand, and it has moved up to rank 8 from 11% in Q2 FY '26 -- FY '26. According to IQ, the umbrella brand Zerodol has surpassed INR 1,500 crores in sales as of September 2026. Per IQ, it now stands as the fourth largest brand within IPM. In the chronic segment, as of September 2006, Ipca recorded growth of around, against IPM growth of roughly 17%.

Ajit Kumar Jain executive
#4

On the IP side, in the acute segment, kaasachieved growth of roughly 11%, and we're matching the overall market growth in acute there, mainly because certain parts of the portfolio, such as anti-malarials and antibacterials — antimalarials are declining, antibacterial is growing only marginally, and even cogen cold is growing quite slowly. On the export formulation business, on a stand-alone basis, IPCA grew 32% in Q2 FY '27 to about INR 653 crores, versus INR 493 crores in Q2 FY '26. Our promotional branded business in ROW markets delivered 19% growth for Q2 FY '27, to roughly INR 172 crores against INR 145 crores in Q2 FY '26. The generic market, excluding tender, delivered about 36% growth in Q2 FY '27, to around INR 364 crores versus Q2 FY '26. The institutional generics business delivered growth of approximately 45% for the quarter. And API delivered growth of about 6% for the quarter. Consolidated Q2 FY '26 business grew by roughly 14%, to about INR 2,910 crores against INR 2,557 crores. For Q2 FY '27, we continue to see significant price increases on inputs, logistics cost, shipping cost, and even fuel and your energy cost.

Ajit Kumar Jain executive
#5

Even with all of those factors in play, consolidated EBITDA margins overall came in better, at approximately 22.97% for Q2 FY '27, compared with 21.68% for Q2 FY '26. At IPCA, the stand-alone EBITDA margin also rose, reaching 26.6% in Q2 FY '27 versus 25.4% in Q2 FY '26. Now that I've laid out the headline figures, I'd like to invite participants to pose their questions.

Operator operator
#6

<<operator_script>> Our first question comes from Saion Mukherjee at Nomura.

Saion Mukherjee analyst
#7

I'd like to ask about the Zerodol franchise. What kind of growth are you seeing there? And could you break that down between volume and price increase? Also, how much headroom is there for this franchise to grow? What would the key drivers be? And are you seeing any competitive pressure in the market?

Ajit Kumar Jain executive
#8

So overall, let's say from April through September, looking at our pain segment, it has increased roughly 14%, going from INR 1,065 crores to around INR 1,116 crores, based on 1,000 internal numbers starting at INR 1,206. So we are — it keeps expanding at 14% during the first half of this year. And actually, in Q2 — this quarter of the present financial year — within the pain segment, we've seen growth of about 16% — the total pain segment posted a figure of roughly INR 628 crores, up from INR 543 crores. So we've logged close to 16% growth. So on an ongoing basis, both of our portfolios — rheumatoid arthritis and osteoarthritis, which includes drool in all rheumatoid arthritis products — continue to perform and continue to expand in that roughly 14% to 15% kind of range. So we have zero concern about that. And in fact, starting from the current INR 1,500 crores umbrella brand, we expect a similar kind of growth to carry on for the next 3, 4 years, yes.

Saion Mukherjee analyst
#9

Of that growth, let's say 14% to 16%, how much would be led by volume?

Ajit Kumar Jain executive
#10

We're probably looking at volume grade growth of close to 8% to 9%. Price growth, meanwhile, is likely to land around 4%, 4.5%, yes.

Saion Mukherjee analyst
#11

Also, do you anticipate that the momentum in volume growth will keep up?

Ajit Kumar Jain executive
#12

Yes.

Saion Mukherjee analyst
#13

Alright. And sir, one more question concerned the guidance on growth and margin — could you restate those figures, along with any updated view you hold for FY '27?

Ajit Kumar Jain executive
#14

During prior quarters—specifically, in that earlier quarter—we provided guidance indicating overall growth of roughly 12% to 13%, which was later revised to 14% to 16%. That stays as is. Consolidated EBITDA margin guidance, which stood at 22% to 23%, will likewise remain unchanged.

Saion Mukherjee analyst
#15

And sir, what would yours be?

Ajit Kumar Jain executive
#16

The guidelines aren't being revised.

Saion Mukherjee analyst
#17

Alright. Yes, sir — and regarding the medium-term EBITDA expectation, say across the coming 2 to 3 years, what level do you anticipate for the consolidated elected EBITDA margin?

Ajit Kumar Jain executive
#18

Each year, we ought to be getting better by roughly 1% to 1.25% in EBITDA on a consolidated basis — and IPCA EBITDA will move up by approximately stand-alone EBITDA.

Operator operator
#19

<<operator_script>> Our following question comes from Shashank Kushnakumar, who is calling on the line from Emkay Global.

Shashank Krishnakumar analyst
#20

I guess for Unichem QQ this quarter, we saw a sharp uptick in gross margin — could you just share what drove that, and whether that's a figure we can work with going forward as well? And also for Unichem, are we sticking with the earlier guidance of top line growth and around 13% margins.

Ajit Kumar Jain executive
#21

So looking at Unichem, we've delivered close to about 20%, with an EBITDA margin of 11.3% in the current quarter. I think on the whole, freight went up quite a bit during this particular quarter because of the freight increase. And freight figures — roughly INR 30 crores extra went into this quarter. If you look at Unichem's other expenditure, it moved from INR 142 crores to INR 19 crores. So that's an increase of close to about 47% — INR 47 crores in other expenses, and of that, almost INR 31.2 crores is just the rise in freight expenses. Also, because of the significant jump in overall freight costs and also, let's say, a bit of an overall increase, your air shipment has gone up too, because of the overall time — the shipping lines take to deliver the goods and all that. So some consignments had to go by air and all. Air as a percentage of the overall went up in this quarter from 5%, 6% to around 25%. So that has taken roughly INR 30 crores out of freight expenses out of EBITDA that has grown — and that has resulted in a somewhat lower EBITDA margin.

Ajit Kumar Jain executive
#22

Beyond that, I’d say the European business has performed well. In Brazil, they had been posting losses during the first 2 quarters of this financial year, and now it has started generating profit. So going forward, that business will gradually improve as well. If conditions return to normal, margins can rise. However, should freight and all those costs — energy costs — stay elevated, then it might stay in the 11% to 13% range, something like that. EBITDA margin.

Shashank Krishnakumar analyst
#23

Understood. And the gross margin we recorded this quarter is sustainable on a spec basis, at nearly 8%.

Ajit Kumar Jain executive
#24

It might be 1% or 2% in a few spots, mainly since input costs keep swinging around so much. Yes.

Shashank Krishnakumar analyst
#25

And sir, could you also highlight how much the U.S. portfolio grew — both for IPCA, which is being booked in Unichem, and for the Unichem portfolio during this quarter?

Ajit Kumar Jain executive
#26

So overall, in the U.S., if we look at dollar terms, total portfolio growth came in at roughly 9%, and for the IPCA portfolio, value growth was approximately 74% in dollar terms. I'd say the card portfolio delivered close to $5.8 million in sales for the quarter. And Unichem's portfolio reached about $38.5 million for the quarter.

Operator operator
#27

Rashmi Shetty from Dolat Capital has the next question on the line.

Rashmi Sancheti analyst
#28

Regarding the institutional segment, sir — the figure is 3 billion INR, or 300 crores, for this year, and we've already completed INR 236 crores in the first. Do you feel it will be lumpy and that second-half sales will be pretty low? Or are you upgrading the guidance for that?

Ajit Kumar Jain executive
#29

For our institutional segment, we typically avoid issuing any particularly aggressive guidance, since the character of this business makes us prefer to stay very conservative. This year, when that guidance was provided, a substantial volume of shipments meant for the prior fiscal year moved into the first quarter of the current year because ships were unavailable and other operations were affected — that shipment came to roughly INR 25 crores. Even so, we posted solid growth in the second quarter of this financial year as well, and that trend should carry on. Still, we don't anticipate growth of this magnitude.

Rashmi Sancheti analyst
#30

All right. So for the time being, we should keep that figure of INR 300 crores for the full year — the INR 300 crores.

Ajit Kumar Jain executive
#31

It will definitely go past that, since this INR 25 crores was never factored into the guideline at all. So it might end up at INR 325, INR 330, 340. But overall, we don't see this business growing meaningfully. It could also decline next year, here and there.

Rashmi Sancheti analyst
#32

Understood. Understood, sir. And sir, regarding the branded side of the business, we are still holding to that 15% growth figure. So for Generics and the banked business, we ought to anticipate a somewhat softer quarter in H2, correct, in order to hit the guidance?

Ajit Kumar Jain executive
#33

Generics are performing well for us. Overall, we're seeing solid growth. And on the branded side, broadly speaking, during the first half of this year, growth came in at roughly 22%, with the exception of 1 specific geography where West Asia shipments were delayed, which caused that business to dip slightly, by 3%. That said, every other market has actually grown quite nicely. So we're holding to our guidance of 15% to 16% growth for India overall.

Rashmi Sancheti analyst
#34

Alright. And sir, regarding the bookkeeping question. On the interest cost side, you all have paid back a portion of the long-term borrowing, yet interest cost remained elevated in quarter 2. If you could shed some light on that? And what should we expect for the run rate in quarter 3 and quarter 4.

Ajit Kumar Jain executive
#35

During quarter 2, our interest cost has declined as well. The reason it hasn't risen is that in the prior year we repaid all of our foreign currency debt that was outstanding and on the books, since we were holding the cash — so before this, around the time the rupee began depreciating, we decided to pay off every dollar-denominated loan in our books. As things stand, we have just a very small borrowing of roughly INR 155 crores on a rupee term loan, and by year-end that will probably increase by about INR 70 crores to INR 75 crores. I believe that will be the balance going forward, and in practical terms we are a debt-free company, because we hold close to INR 700 crores of cash on the books, plus or Harlan. We aren't repaying that debt either, because it was contracted at a very low rate relative to the current market rate we are earning by deploying money in mutual funds and so on. So we are not prepaying that debt.

Rashmi Sancheti analyst
#36

Right, I got it. What I was trying to say is that the INR 12 crores run rate we achieved across the last 2 quarters—that figure ought to come down in H2, correct, on account of the debt.

Ajit Kumar Jain executive
#37

Yeah, it would go down — yes, it will decline, yes.

Operator operator
#38

<<operator_script>> Our following question comes from Nitin Agarwal with DAM Capital Advisors.

Nitin Agarwal analyst
#39

I’ve just got a couple of questions from my end. Sir, regarding the — could you provide us with a bit more detail on how the U.K. and Europe business is doing — the U.K., Europe, and Australia business — this quarter in the first half?

Ajit Kumar Jain executive
#40

Yeah, I'll provide that figure. On the generics side overall, looking at Q2, the European business grew by roughly 23%, Australia and New Zealand grew by roughly 24%. The U.S. grew by 31%. Canada grew by 5%, and the South African business grew by 46%. So overall, most of the businesses in Gatwick performed well. Yes.

Nitin Agarwal analyst
#41

Regarding the U.K., we've encountered occasional problems there from time to time. So has that business now stabilized in the U.K.?

Ajit Kumar Jain executive
#42

As my portfolio keeps expanding in the U.K. In the last financial year, we ran into a lot of trouble because, let's say, our portfolio was simply made up of very old products — perhaps genesis 15, 20 years old — and those items were being sold in the market below cost. So last year in Europe, in the U.K., we have the U.K. portfolio, and across the whole year we took a hit of roughly 2.5 million in the way of loss in the U.K. But given that kind of situation, there is plenty of disruption in the U.K. market today, with many products going into short supply and so on. And prices are coming back, since the practice of selling product at a lower price cannot go on for long. So that has shifted in the European — this U.K. subsidiary has also posted profit this year, and the U.K. business overall is now improving.

Nitin Agarwal analyst
#43

And sir, regarding our subsidiaries, could you update us on how the various subsidiaries have performed?

Ajit Kumar Jain executive
#44

Other than one subsidiary — and that one is disclosed — every subsidiary has performed well, and all of them are profitable here. A few need a bit more time, since there are solid order positions on their API side. So perhaps, I think, by next financial year, things will begin to improve there.

Operator operator
#45

<<operator_script>> Seeing no additional questions from the participants, I'll now turn the conference back to management for closing remarks. Thank you, and over to you, sir.

Executive executive
#46

Yes. Thank you, Madam. Since every question has now been answered, I believe we can wrap things up on car. Thank you all for joining this phone call.

Operator operator
#47

Much appreciated, sir. As representatives of DAM Capital Advisors Limited, we bring this conference call to a close. Many thanks to everyone for being with us, and at this point you're welcome to hang up your lines. Thanks so much.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Ipca Laboratories Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Ipca Laboratories Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.